Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 2
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
Molina-Henry DP, Raman R, Liu A, Langford O, Johnson K, Shum LK, Glover CM, Dhadda S, Irizarry M, Jimenez-Maggiora G, Braunstein JB, Yarasheski K, Venkatesh V, West T, Verghese PB, Rissman RA, Aisen P, Grill JD, Sperling RA. Molina-Henry DP, et al. Among authors: raman r. Alzheimers Dement. 2024 Jun;20(6):3827-3838. doi: 10.1002/alz.13803. Epub 2024 Apr 17. Alzheimers Dement. 2024. PMID: 38629508 Free PMC article.
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.
Molina-Henry DP, Raman R, Liu A, Langford O, Braunstein JB, Verghese PB, Venkatesh V, Dhadda S, Irrizary M, Grill JD, Johnson K, Rissman RA, Aisen P, Sperling RA; AHEAD 3‐45 Study Team. Molina-Henry DP, et al. Among authors: raman r. Alzheimers Dement (Amst). 2025 Aug 22;17(3):e70164. doi: 10.1002/dad2.70164. eCollection 2025 Jul-Sep. Alzheimers Dement (Amst). 2025. PMID: 40861822 Free PMC article.
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Grill JD, Flournoy C, Dhadda S, Ernstrom K, Sperling R, Molina-Henry D, Tranotti K, Harris R, Kanekiyo M, Gee M, Irizarry M, Kramer L, Aisen P, Raman R. Grill JD, et al. Among authors: raman r, molina henry d. Ann Neurol. 2024 Feb;95(2):288-298. doi: 10.1002/ana.26819. Epub 2023 Oct 25. Ann Neurol. 2024. PMID: 37830926 Free PMC article.